Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking approval for a new indication of its respiratory drug, Nucala (mepolizumab). The ...

(Alliance News) - GSK PLC on Monday said it has had an application to expand the use of mepolizumab for the treatment of chronic obstructive pulmonary disease accepted for review by the European ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or mepolizumab, to include patients with chronic obstructive pulmonary disease (COPD) ...

Please provide your email address to receive an email when new articles are posted on . Patients began with mepolizumab or benralizumab before switching to continuing with benralizumab at week 52.

Regardless of the presence of nasal polyps and aeroallergen sensitivity, patients with severe eosinophilic asthma can benefit from treatment with mepolizumab. Patients with severe eosinophilic asthma ...